Soleus Capital Master Fund, L.P. 13D and 13G filings for VYNE Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 3:34 pm Sale | 2024-09-30 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 0 0.000% | -703,868 (Position Closed) | Filing |
| 2024-02-02 09:42 am Sale | 2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 703,868 5.000% | -187,000 (-20.99%) | Filing |
| 2023-11-02 4:15 pm Purchase | 2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 890,868 6.400% | 890,868 (New Position) | Filing |